- Home
- CTO vs CRMD Comparison
CTO vs CRMD Comparison
Compare CTO & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTO | CRMD |
|---|---|---|
| Founded | 1902 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 823.9M | 590.7M |
| IPO Year | 1995 | 2009 |
Fundamental Metrics
Financial Performance| Metric | CTO | CRMD |
|---|---|---|
| Price | $21.59 | $8.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $22.50 | $14.83 |
| AVG Volume (30 Days) | 306.3K | ★ 1.4M |
| Earning Date | 04-28-2026 | 05-11-2026 |
| Dividend Yield | ★ 7.44% | N/A |
| EPS Growth | 122.86 | ★ 780.00 |
| EPS | 0.13 | ★ 0.72 |
| Revenue | $149,545,000.00 | ★ $311,709,000.00 |
| Revenue This Year | $7.63 | $0.30 |
| Revenue Next Year | $2.76 | N/A |
| P/E Ratio | $165.31 | ★ $11.71 |
| Revenue Growth | 20.10 | ★ 617.03 |
| 52 Week Low | $15.07 | $6.13 |
| 52 Week High | $22.71 | $13.48 |
Technical Indicators
Market Signals| Indicator | CTO | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 44.85 | 51.79 |
| Support Level | $21.24 | $8.08 |
| Resistance Level | $22.08 | $9.01 |
| Average True Range (ATR) | 0.23 | 0.28 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 26.51 | 27.74 |
Price Performance
Historical ComparisonAbout CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties in diversified markets in the United States. The company operates in four primary business segments: Income properties, management services, commercial loans and investments, and real estate operations. It derives maximum revenue from Income Properties.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.